Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Br J Pharmacol ; 166(1): 258-75, 2012 May.
Article in English | MEDLINE | ID: mdl-22050085

ABSTRACT

BACKGROUND AND PURPOSE: The majority of small molecule compounds targeting chemokine receptors share a similar pharmacophore with a centrally located aliphatic positive charge and flanking aromatic moieties. Here we describe a novel piperidine-based compound with structural similarity to previously described CCR8-specific agonists, but containing a unique phenyl-tetrazol moiety which, in addition to activity at CCR8 was also active at CCR1. EXPERIMENTAL APPROACH: Single point mutations were introduced in CCR1 and CCR8, and their effect on small molecule ligand-induced receptor activation was examined through inositol trisphosphate (IP(3) ) accumulation. The molecular interaction profile of the agonist was verified by molecular modeling. KEY RESULTS: The chemokine receptor conserved glutamic acid in TM-VII served as a common anchor for the positively charged amine in the piperidine ring. However, whereas the phenyl-tetrazol group interacted with TyrIV:24 (Tyr(172) ) and TyrIII:09 (Tyr(114) ) in the major binding pocket (delimited by TM-III to VII) of CCR8, it also interacted with TrpII:20 (Trp(90) ) and LysII:24 (Lys(94) ) in the minor counterpart (delimited TM-I to III, plus TM-VII) in CCR1. A straightening of TM-II by Ala-substitution of ProII:18 confirmed its unique role in CCR1. The extracellular loop 2 (ECL-2) contributed directly to the small molecule binding site in CCR1, whereas it contributed to efficacy, but not potency in CCR8. CONCLUSION AND IMPLICATIONS: Despite high ligand potency and efficacy and receptor similarity, this dual-active and bitopic compound binds oppositely in CCR1 and CCR8 with different roles of ECL-2, thereby expanding and diversifying the influence of extracellular receptor regions in drug action.


Subject(s)
Inositol 1,4,5-Trisphosphate/metabolism , Piperidines/pharmacology , Receptors, CCR1/metabolism , Receptors, CCR8/metabolism , Tetrazoles/pharmacology , Animals , Binding Sites , COS Cells , Chlorocebus aethiops , Glutamic Acid/metabolism , Humans , Ligands , Models, Molecular , Piperidines/chemistry , Piperidines/metabolism , Point Mutation , Receptors, CCR1/agonists , Receptors, CCR1/genetics , Receptors, CCR8/agonists , Receptors, CCR8/genetics , Tetrazoles/chemistry , Tetrazoles/metabolism
2.
J Clin Epidemiol ; 54(12): 1195-203, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11750188

ABSTRACT

Disease-specific registries have many important applications in epidemiologic, clinical and health services research. Since 1989 the Department of Veterans Affairs has maintained a national HIV registry. VA's HIV registry is national in scope, it contains longitudinal data and detailed resource utilization and clinical information. To describe the structure, function, and limitations of VA's national HIV registry, and to test its accuracy and completeness. The VA's national HIV registry contains data that are electronically extracted from VA's computerized comprehensive clinical and administrative databases, called Veterans Integrated Health Systems Technology and Architecture (VISTA). We examined the number of AIDS patients and the number of new patients identified to the registry, by year, through December 1996. We verified data elements against information obtained from the medical records at five VA sites. By December 1996, 40,000 HIV-infected patients had been identified to the registry. We encountered missing data and problems with data classification. Missing data occurred for some elements related to the computer programming that creates the registry (e.g., pharmacy files), and for other elements because manual entry is required (e.g., ethnicity). Lack of a standardized data classification system was a problem, especially for the pharmacy and laboratory files. In using VA's national HIV registry we have learned important lessons, which, if taken into account in the future, could lead to the creation of model disease-specific registries.


Subject(s)
HIV Infections/epidemiology , Registries/standards , Veterans , Humans , Pilot Projects , Program Evaluation , Research Design , United States , United States Department of Veterans Affairs
3.
AIDS ; 12(11): F103-9, 1998 Jul 30.
Article in English | MEDLINE | ID: mdl-9708399

ABSTRACT

OBJECTIVE: A Phase II, open-label, randomized, parallel-arm, multicentre trial to compare the antiviral activity and safety of two formulations of saquinavir (SQV), soft gelatin (SQV-SGC) and hard gelatin (SQV-HGC) capsules, in combination with two nucleoside reverse transcriptase inhibitors (NRTI), in antiretroviral-naive, HIV-1-infected individuals. PARTICIPANTS: A total of 171 people of > or = 13 years, with plasma HIV-1 RNA levels > or = 5000 copies/ml, who had received no protease inhibitor therapy, < or = 4 weeks NRTI therapy and no antiretroviral treatment within 28 days of screening. Eighty-one people were randomized to the SQV-HGC group and 90 to the SQV-SGC group. A total of 148 patients completed 16 weeks of therapy. INTERVENTION: Therapy for 16 weeks with either SQV-SGC 1200 mg or SQV-HGC 600 mg, both three times a day, in combination with two NRTI. RESULTS: Using an on-treatment analysis, patients taking SQV-SGC had a larger reduction in plasma HIV-1 RNA than those taking SQV-HGC (-2.0 versus -1.6 log10 copies/ml). Eighty per cent of those on SQV-SGC had < 400 copies HIV RNA/ml, compared with 43% in the SQV-HGC group (P = 0.001). A statistically significant difference in the area under the curve (AUC) values between the SQV-SGC and SQV-HGC arms (-1.7 versus -1.5 log10 copies/ml, respectively; P = 0.0054) was observed when withdrawals prior to week 12, major protocol violators and patients with < 75% compliance were excluded from the analysis; however, the difference between the values for the intent-to-treat population was not significant (P = 0.1929). Adverse events (mostly mild) included diarrhoea and nausea. CONCLUSIONS: SQV-SGC was generally well tolerated and gave significantly more potent suppression of plasma HIV-1 RNA in antiretroviral-naive patients than SQVHGC.


Subject(s)
Anti-HIV Agents/therapeutic use , Gelatin , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , HIV-1 , Saquinavir/therapeutic use , Adolescent , Adult , Anti-HIV Agents/administration & dosage , CD4 Lymphocyte Count , Chemistry, Pharmaceutical , Consumer Product Safety , Drug Therapy, Combination , Female , HIV Infections/immunology , HIV Infections/virology , HIV Protease Inhibitors/administration & dosage , HIV-1/genetics , Humans , Male , Middle Aged , RNA, Viral/blood , Saquinavir/administration & dosage
4.
J Acquir Immune Defic Syndr Hum Retrovirol ; 11(2): 142-50, 1996 Feb 01.
Article in English | MEDLINE | ID: mdl-8556396

ABSTRACT

Following a 4-year controlled trial comparing early and later zidovudine treatment, we conducted an additional 3-year follow-up. Of the original 338 patients, 275 participated. Clinical outcome measures were AIDS and death. In the early therapy group (n = 170), 67 patients progressed to AIDS compared with 85 in the later therapy group (n = 168); the relative risk (RR) comparing early with later therapy was 0.72% (95% confidence interval [CI] 0.52-0.99; p = 0.044). The early therapy group had 74 deaths compared with 73 in the later therapy (RR = 0.98; 95% CI, 0.71-1.36; p = 0.91). The early group had a peak CD4+ count increase at 1-2 months and a delay of 1 year before CD4+ counts fell below baseline. For patients who received zidovudine for more than the median duration (20.3 months) before their first AIDS diagnosis, the RR for death was 2.08 (95% CI, 1.36-3.19, p = 0.001). Additional factors independently associated with poor prognosis following AIDS were a CD4+ count of < 100 cells/mm3 and increased severity of the first AIDS diagnosis, whereas use of another antiretroviral agent was associated with improved survival. We conclude that early zidovudine therapy delays progression to AIDS but does not affect survival. Patients who progress to AIDS while on prolonged zidovudine monotherapy many benefit from a change to other antiretroviral therapy(ies).


Subject(s)
Antiviral Agents/therapeutic use , HIV Infections/drug therapy , Zidovudine/therapeutic use , Acquired Immunodeficiency Syndrome/etiology , Acquired Immunodeficiency Syndrome/mortality , Adult , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/immunology , Cohort Studies , Disease Progression , Double-Blind Method , Female , Follow-Up Studies , HIV Infections/immunology , HIV Infections/physiopathology , Humans , Longitudinal Studies , Male , Randomized Controlled Trials as Topic , Survival Rate , Veterans
5.
Biol Bull ; 190(3): 336-349, 1996 Jun.
Article in English | MEDLINE | ID: mdl-29227696

ABSTRACT

Anatomical and behavioral aspects of reproduction in female Dungeness crab, Cancer magister, were investigated. Female crabs were collected over a two-year period and external indicators of reproductive condition were recorded. A subset of crabs was retained for macroscopic and histological examination of the reproductive tract. In addition, males and females were held in the laboratory for mating observations, thus providing females of known mating history for dissection. The spermatheca is of the "ventral type," i.e., the vagina and the oviduct open into the spermatheca in close proximity to each other. A novel organ that often contains sperm, the bursa, is separate and distinct from the spermatheca in both position and origin and is reported for the first time for a brachyuran crab. The bursa is located just inside the vulva, distal to the spermatheca, and opens into the vagina. The sperm plug of C. magister, described here for the first time, is unique in form among cancrids. The sperm plug is placed in the vagina by the first male to mate with a soft-shelled female and prevents subsequent access to the spermatheca. However, the sperm plug does not occlude the vulva nor prevent subsequent copulation; ejaculates from subsequent matings are deposited in the bursa. Hypotheses of the possible function of the bursa are discussed.

6.
Arch Neurol ; 48(2): 203-9, 1991 Feb.
Article in English | MEDLINE | ID: mdl-1993012

ABSTRACT

Human immunodeficiency virus (HIV)-infected individuals often demonstrate neuropsychiatric impairment; however, it is unclear how brain metabolism may be altered in such patients. We used in vivo phosphorus 31 magnetic resonance spectroscopy to noninvasively assess brain energy and phospholipid metabolism by measuring brain concentrations of adenosine triphosphate (ATP), phosphocreatine (PCr), and inorganic phosphate (Pi), as well as phospholipid compounds and intracellular pH. In study 1, 17 HIV-seropositive men with varying degrees of neuropsychiatric impairment and six control subjects were studied. Localized spectra were obtained from a heterogeneous 5 x 5 x 5-cm volume of interest (VOI). Patients with HIV infection had a significantly lower ATP/Pi ratio and a trend for a lower PCr/Pi ratio than did the control group. In addition, the ATP/Pi and PCr/Pi ratios were both significantly negatively correlated with overall severity of neuropsychiatric impairment. In study 2, three HIV-seropositive men with neuropsychiatric impairment were compared with 11 HIV-seronegative men. Localized phosphorus 31 magnetic resonance spectra were obtained from two relatively homogeneous VOIs: (1) a predominantly white matter VOI, and (2) a predominantly subcortical gray matter VOI. The three HIV-infected patients demonstrated significantly decreased ATP and PCr concentrations in the white matter VOI. These results suggest that HIV infection of the brain may impair brain cellular oxidative metabolism and that the degree of metabolic compromise may be related to the severity of neuropsychiatric impairment.


Subject(s)
HIV Infections/metabolism , Nervous System Diseases/etiology , AIDS Dementia Complex/metabolism , AIDS Dementia Complex/pathology , Adenosine Triphosphate/metabolism , Adult , Brain/pathology , Female , HIV Infections/complications , HIV Infections/pathology , Humans , Hydrogen-Ion Concentration , Intracellular Fluid , Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy , Male , Middle Aged , Nervous System Diseases/metabolism , Nervous System Diseases/pathology , Phosphates/metabolism , Phosphocreatine/metabolism , Phospholipids/metabolism
7.
8.
Eur J Clin Invest ; 17(6): 530-7, 1987 Dec.
Article in English | MEDLINE | ID: mdl-3123252

ABSTRACT

The bisphosphonate whole body retention test (WBR) has been used to estimate bone mineralization rate (bone turnover). Bisphosphonates given i.v. are taken up by bone or excreted in urine. The aim of the present investigation was to test the efficacy of WBR in estimating bone mineralization rate (m) and to evaluate the influence of renal function (Clcr) and bone mass (forearm bone mineral content; BMC) on WBR. The 24-h retention of 3.7 MBq 99mTc-HMBP (1-hydroxymethylene-1,1-bisphosphonate) (Osteoscan) given i.v. was measured by a medium sensitive whole body counter in thirty-one patients with hyperparathyroidism (n = 14), hyperthyroidism (n = 8) or hypothyroidism (n = 9) (group 1) and in seventy-six females with postmenopausal spinal crush fracture osteoporosis (group 2). In the same individuals m was calculated from a 7-day 47Ca-kinetic study using the expanding calcium pool model. Multiple regression analysis of WBR vs. m and Clcr in group 1 disclosed that WBR correlated positively to m [rp = 0.49, P less than 0.01 (rp = partial correlation coefficient)] and inversely to Clcr (rp = -0.44, P less than 0.02). Inclusion of BMC in the analysis did not reveal any significant partial correlation between WBR and BMC (rp = -0.33, 0.05 less than P less than 0.10). In group 2 WBR correlated inversely to Clcr (rp = -0.48, P less than 0.001) but showed no significant relation to m (rp = 0.10, NS).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Bone Diseases, Metabolic/metabolism , Bone and Bones/metabolism , Minerals/metabolism , Osteoporosis/metabolism , Technetium Tc 99m Medronate/analogs & derivatives , Adult , Aged , Female , Humans , Kidney/physiopathology , Male , Middle Aged , Regression Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...